Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome

American Journal of Kidney Diseases

Volumn 65, Issue 2, 2015, Pages 342-

  Wetzels, Jack F M ^a   Van De Kar, Nicole C A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

DISEASE ACTIVITY; DRUG WITHDRAWAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FUNCTION; LETTER; MAINTENANCE THERAPY; MUTATION; RECURRENT DISEASE; TREATMENT DURATION; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMOGLOBINURIA; MALE; QUALITY OF LIFE; TREATMENT WITHDRAWAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMOGLOBINURIA; HUMANS; MALE; QUALITY OF LIFE; WITHHOLDING TREATMENT;

EID: 84921481864     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.04.039     Document Type: Letter

References (1)

1. G. Ardissino, S. Testa, and I. Possenti Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases Am J Kidney Dis 64 4 2014 633 637